These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35525812)

  • 1. Corrigendum to "AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma" [Canc. Lett. 414 (2018) 71-80].
    Wang LL; Jin XH; Cai MY; Li HG; Chen JW; Wang FW; Wang CY; Hu WW; Liu F; Xie D
    Cancer Lett; 2022 Jul; 539():215700. PubMed ID: 35525812
    [No Abstract]   [Full Text] [Related]  

  • 2. AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma.
    Wang LL; Jin XH; Cai MY; Li HG; Chen JW; Wang FW; Wang CY; Hu WW; Liu F; Xie D
    Cancer Lett; 2018 Feb; 414():71-80. PubMed ID: 29126912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum to "Circadian clock gene NPAS2 promotes reprogramming of glucose metabolism in hepatocellular carcinoma cells" [Canc. Lett. 469 (2020) 498-509].
    Yuan P; Yang T; Mu J; Zhao J; Yang Y; Yan Z; Hou Y; Chen C; Xing J; Zhang H; Li J
    Cancer Lett; 2021 Nov; 521():322-323. PubMed ID: 34521548
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrigendum to "NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma" [Canc. Lett. 476 (2020) 48-56].
    Leung HW; Lau EYT; Leung CON; Lei MML; Mok EHK; Ma VWS; Cho WCS; Ng IOL; Yun JP; Cai SH; Yu HJ; Ma S; Lee TKW
    Cancer Lett; 2021 Feb; 499():2. PubMed ID: 32563702
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways" [Canc. Lett. 337 (2013) 226-236].
    Bao L; Yan Y; Xu C; Ji W; Shen S; Xu G; Zeng Y; Sun B; Qian H; Chen L; Wu M; Chen J; Su C
    Cancer Lett; 2020 Mar; 473():198-199. PubMed ID: 31926781
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to "Long non-coding RNA Unigene 56159 promotes epithelial-mesenchymal transition by acting as a ceRNA of miR-140-5p in hepatocellular carcinoma cells" [Canc. Lett. 382 (2016) 166-175].
    Lv J; Fan HX; Zhao XP; Lv P; Fan JY; Zhang Y; Liu M; Tang H
    Cancer Lett; 2020 Mar; 472():181-182. PubMed ID: 31879079
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "LncRNA n335586/miR-924/CKMT1A axis contributes to cell migration and invasion in hepatocellular carcinoma cells" [Canc. Lett. 429 (2018) 89-99].
    Fan H; Lv P; Mu T; Zhao X; Liu Y; Feng Y; Lv J; Liu M; Tang H
    Cancer Lett; 2020 Dec; 494():84-87. PubMed ID: 32911100
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "cPLA2α activates PI3K/AKT and inhibits Smad2/3 during epithelial-mesenchymal transition of hepatocellular carcinoma cells" [Canc. Lett. 403 (2017) 260-270].
    Fu H; He Y; Qi L; Chen L; Luo Y; Chen L; Li Y; Zhang N; Guo H
    Cancer Lett; 2021 Feb; 498():240-241. PubMed ID: 33221059
    [No Abstract]   [Full Text] [Related]  

  • 9. High expression of AGBL2 is a novel prognostic factor of adverse outcome in patients with ovarian carcinoma.
    He WP; Wang LL
    Oncol Lett; 2019 Nov; 18(5):4900-4906. PubMed ID: 31612000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum to "Targeting autophagy in cancer stem cells as an anticancer therapy" [Canc. Lett. 393 (2017) 33-39].
    Lei Y; Zhang D; Yu J; Dong H; Zhang J; Yang S
    Cancer Lett; 2018 Mar; 416():149. PubMed ID: 29307478
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Forkhead box D1 promotes EMT and chemoresistance by upregulating lncRNA CYTOR in oral squamous cell carcinoma" [Canc. Lett. 503 (2021) 43-53].
    Chen S; Yang M; Wang C; Ouyang Y; Chen X; Bai J; Hu Y; Song M; Zhang S; Zhang Q
    Cancer Lett; 2022 Jul; 537():215688. PubMed ID: 35459579
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "miR-371-5p down-regulates pre mRNA processing factor 4 homolog B (PRPF4B) and facilitates the G1/S transition in human hepatocellular carcinoma" [Canc. Lett. 335 (2013) 351-360].
    Liu RY; Diao CF; Zhang Y; Wu N; Wan HY; Nong XY; Liu M; Tang H
    Cancer Lett; 2021 May; 505():87-90. PubMed ID: 33685752
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer" [Canc. Lett. 459(2019)204-215].
    Zhang B; Ye H; Ren X; Zheng S; Zhou Q; Chen C; Lin Q; Li G; Wei L; Fu Z; Zhang Y; Hu C; Li Z; Chen R
    Cancer Lett; 2022 Nov; 548():215897. PubMed ID: 36050250
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B" [Canc. Lett. 535 (2022) 215629].
    Liu Y; Zhang Z; Gao X; Ma Q; Yu Z; Huang S
    Cancer Lett; 2022 Jul; 539():215701. PubMed ID: 35527117
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "SUMOylation of SYNJ2BP-COX16 promotes breast cancer progression through DRP1-mediated mitochondrial fission" [Canc. Lett. 547 (2022) 215871].
    Wang M; Wei R; Li G; Bi HL; Jia Z; Zhang M; Pang M; Li X; Ma L; Tang Y
    Cancer Lett; 2022 Nov; 549():215923. PubMed ID: 36166936
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "Voltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer" [Canc. Lett. 500 (2021) 119-131].
    Sui Q; Peng J; Han K; Lin J; Zhang R; Ou Q; Qin J; Deng Y; Zhou W; Kong L; Tang J; Xiao B; Li Y; Yu L; Fang Y; Ding PR; Pan Z
    Cancer Lett; 2021 Sep; 516():57-60. PubMed ID: 34091433
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM." [Canc. Lett. 449 (2019) 31-44].
    Xie R; Chen X; Chen Z; Huang M; Dong W; Gu P; Zhang J; Zhou Q; Dong W; Han J; Wang X; Li H; Huang J; Lin T
    Cancer Lett; 2021 Mar; 500():292-293. PubMed ID: 33390287
    [No Abstract]   [Full Text] [Related]  

  • 18. Retraction notice to "Long non-coding RNA LINC00160 functions as a decoy of microRNA-132 to mediate autophagy and drug resistance in hepatocellular carcinoma via inhibition of PIK3R3" [Canc. Lett. 478 (2020) 22-33].
    Zhang W; Liu Y; Fu Y; Han W; Xu H; Wen L; Deng Y; Li K
    Cancer Lett; 2022 Nov; 549():215933. PubMed ID: 36216654
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation" [Canc. Lett. 494 (2020) 121-131].
    Yin H; Wang X; Zhang X; Zeng Y; Xu Q; Wang W; Zhou F; Zhou Y
    Cancer Lett; 2022 Sep; 543():215792. PubMed ID: 35718664
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233].
    Moskovich D; Alfandari A; Finkelshtein Y; Weisz A; Katzav A; Kidron D; Edelstein E; Veroslavski D; Perets R; Arbib N; Kadan Y; Fishman A; Lerer B; Ellis M; Ashur-Fabian O
    Cancer Lett; 2023 Jun; 563():216196. PubMed ID: 37104919
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.